Skip to main content

Table 2 Per-cancer characteristics of low- and high-risk patients

From: The impact of pharmacokinetic gene profiles across human cancers

 

Low-risk cohort

High-risk cohort

N

Age

Stage 1 or 2

Stage 3 or 4

Grade 1 or 2

Grade 3 or 4

N

Age

Stage 1 or 2

Stage 3 or 4

Grade 1 or 2

Grade 3 or 4

Any-Hit Model

 GBM

125

62 ± 13.3

9

52 ± 23.7

 BRCA

697

59 ± 13.3

533

164

118

53 ± 13.3

96

22

 OV

159

58 ± 10.4

9

150

17

142

103

57 ± 13.3

10

93

19

84

 KIRC

456

61 ± 13.3

389

67

211

245

14

58.5 ± 11.1

2

12

1

13

 LUAD

319

67 ± 10.4

246

73

10

62.5 ± 12.6

6

4

 UCEC

289

63 ± 10.4

226

63

164

125

44

61.5 ± 9.6

13

31

12

32

 HNSC

287

61 ± 11.9

136

151

199

78

16

56.5 ± 10.4

14

2

11

5

 LUSC

198

68.5 ± 8.2

152

46

14

65.5 ± 8.9

12

2

Therapy Efficacy Model

 GBM

127

61 ± 13.3

7

52 ± 23.7

 BRCA

776

58 ± 13.3

602

174

0

0

39

53 ± 13.3

27

12

 OV

228

58 ± 11.1

16

212

31

197

34

60.5 ± 11.9

3

31

5

29

 KIRC

463

61 ± 13.3

390

73

212

251

7

54 ± 8.9

1

6

0

7

 LUAD

321

67 ± 10.4

247

74

0

0

8

67 ± 10.4

5

3

 UCEC

310

63 ± 10.4

231

79

168

142

23

61 ± 10.4

8

15

8

15

 HNSC

288

61 ± 11.9

137

151

200

78

15

57 ± 13.3

13

2

10

5

 LUSC

202

68.5 ± 8.2

155

47

0

0

10

65 ± 8.9

9

1